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Predicting clinical outcome in the elderly renal transplant re- or waiting for kidney transplants has been steadily in-
cipient. creasing over the last decade. For example, in 1997, 36%
Background. The purpose of this study was to evaluate graft of all kidney transplants were performed in patients 50and patient survival in first-time kidney transplant recipients
years or older, and 5.7% of transplants were in patients60 years old or older, and to identify pretransplant risk factors
age 65 or older [5]. Currently, 44% of all patients waitingthat predict clinical outcome.
Methods. We reviewed the clinical course of 206 recipients, for a cadaveric kidney are over age 50 [5]. Graft survival
60 years old or older, of first kidney transplants at the Univer- following transplantation in older patients has been
sity of Minnesota. Patient and graft survival were compared worse than the results for younger patients primarilywith 1640 patients aged 18 to 59 transplanted during the same
because of more graft loss secondary to patient deathtime period. Regression analysis was performed to identify risk
[6–13]. In contrast, loss of grafts secondary to rejectionfactors that predicted a poor outcome.
Results. In patients 60 years old or older, graft survival at is less common in the older transplant patient [6–10].
one and five years was 86 and 60%, and patient survival at one The rising incidence of ESRD in the elderly, combined
and five years was 90 and 68%, respectively. Graft and patient
with a growing shortage of donor kidneys, has generatedsurvival were decreased compared with recipients aged 18 to
much controversy and debate regarding the appropriate-59, but were similar when censored for patient death as a cause
of graft loss. A pretransplant history of nonskin malignancy ness of transplantation in this group of patients with a
and vascular disease and a current smoking history were risk shortened life expectancy [2, 4]. Furthermore, there is a
factors for decreased graft and patient survival. To determine subset of older patients who do poorly, either losing their
the potential impact of screening for low-risk patients, we eval-
grafts and/or dying soon after transplantation. Minimaluated graft and patient survival in patients age $60 without
information is available regarding factors predicting out-these risk factors versus those with one or more risk factors.
In the absence of risk factors, both graft and patient survival come of transplantation in the older ESRD patient mak-
were significantly improved compared with patients with these ing the decision of who should be transplanted even
risk factors and were equivalent to that of patients aged 18 to 59. more difficult. Consequently, some elderly patients whoConclusions. Renal transplantation is a safe and effective
are accepted for transplantation do poorly while otherstherapy for the older renal failure patient. In the absence of
who may have had excellent outcomes are deemed unac-identified risk factors, graft survival is equivalent to that seen
in younger patients. ceptable candidates.
The purpose of this study was to evaluate graft and
patient survival in first-time kidney transplant recipients
The elderly are the fastest growing population of pa- age 60 or older, and to identify pretransplant risk factors
tients with end-stage renal disease (ESRD) [1–3]. In 1996, that predicted clinical outcome.
46% of the 73,000 new ESRD patients were over age
65 [3]. By the year 2000, it is estimated that 60% of all
METHODSESRD patients will be over age 65 [4]. Transplantation
Patient populationhas emerged as a viable option for selected older patients
with renal failure. The number of older patients receiving We reviewed the course of 206 consecutive primary
renal allograft recipients, aged 60 or older, transplanted
at the University of Minnesota between 1980 and 1997.Key words: transplant outcome, graft survival, renal transplantation,
end-stage renal disease. The majority of these patients (70%, N 5 144) were
transplanted since 1990. Graft survival and patient sur-Received for publication August 12, 1999
vival in these older patients were compared with 1640and in revised form November 23, 1999
Accepted for publication December 18, 1999 primary renal allograft recipients aged 18 to 59 trans-
planted at the University of Minnesota during the sameÓ 2000 by the International Society of Nephrology
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Table 1. Characteristics of patients Table 2. Potential predictors of outcome
Age 18 to 59 Age 601 Recipient factors
• AgeCharacteristic N 5 1640 N 5 206
— 60 to 64
Age mean6SEM 3961 6463 — 65 to 70
Sex % female:male 38:62 39:61 — .70
Race % • Gender
Caucasian 90 91 • Race
Black 4 5 • Cause of ESRD
Native American 3 2 • Pre-transplant history of:
Other 3 2 — Coronary artery disease
Cause of ESRD % — Peripheral vascular disease
Diabetes 45 25 — Gastrointestinal or liver disease
GN 24 20 — Pulmonary disease
HTN 3 17 — Diabetes
PCKD 8 16 — Malignancy
Tubulointerstitial 4 9 — Tobacco use
Dialysis prior to transplant % yes:no 81:19 81:19 • Time on the cadaver waiting list
Donor source % • Delayed graft function
Cadaver 44 62 Donor factors
Living 56 38 • Cadaver vs. living
• AgeAbbreviations are: ESRD, end-stage renal disease; GN, glomerulonephritis;
HTN, hypertension; PKD, polycystic kidney disease. — ,10
— 10 to 50
— .50
time period. Patient characteristics are shown in Table
1. The mean age of the older group of patients was 64,
with a range of 60 to 76. Fourteen patients were aged Statistical analysis
70 or older. Routine pretransplant evaluation of patients
Actuarial patient and graft survival rates were calcu-
has been described previously [9]. Most patients with
lated by Kaplan–Meier methods, and a generalized Wil-diabetes or a history of coronary artery disease under-
coxon test was used for statistical comparisons [14]. Graftwent coronary angiography and revascularization prior
and patient survival in these older recipients was com-to transplantation. In other patients, the extent of the
pared with that of patients aged 18 to 59, who werecardiac evaluation was not standardized. In our older
transplanted during the same time period. Graft survivalpopulation, 39% underwent pretransplant coronary an-
rates were calculated with and without death with func-giography, and an additional 15% had a cardiac stress
tion considered a graft loss [15].test performed prior to transplantation. All patients re-
Cox proportional hazards models were used to evalu-ceived blood group-compatible kidneys. For the older
ate the potential predictors of graft and patient survivalpatients, 62% of the kidneys were from cadaver donors
listed in Table 2. Except for smoking history, a completecompared with 44% for the younger group of patients.
data set was available for 187 patients. The analysis wasImmunosuppressive regimens during this time period
repeated in a subset of 155 patients in whom an accuratehave been previously described [9]. Between 1980 and
smoking history was obtained. Cardiac disease was de-1984, patients were randomized to receive Minnesota
fined as either a documented history of myocardial in-antilymphocyte globulin (MALG), prednisone, and aza-
farction or angiographically proven stenosis of $70% ofthioprine versus cyclosporine (14 mg/kg/day for the first
at least one coronary artery. Peripheral vascular diseaseweek then 12 mg/kg/day) and prednisone. Since 1984,
was defined as clinically significant cerebral, aortic, orall living donor kidney recipients have received triple
lower extremity arterial disease or a history of deeptherapy consisting of cyclosporine (4 mg/kg/twice daily),
venous thrombosis. Gastrointestinal and liver diseaseprednisone (1 mg/kg/day tapered to 0.4 mg/kg/day by
was defined as a documented history of peptic ulcerone month and to 0.15 mg/kg/day by one year), and
disease, active viral hepatitis or unexplained persistentazathioprine. Cadaver kidney recipients received se-
hepatic enzyme elevation, biopsy-proven cirrhosis, di-quential therapy with MALG (20 mg/kg/day for 7 days),
verticulitis, or a history of known cholelithiasis withoutprednisone, and azathioprine with delayed introduction
cholecystectomy prior to transplant. Pulmonary diseaseof cyclosporine. Between 1987 and 1991, OKT3 (5 mg/
was defined as clinically significant obstructive or restric-day for 7 days) was randomized versus MALG in the
tive lung disease. The time on the cadaver waiting listsequential therapy protocol. Since 1992, antithymocyte
of less than one year was compared with waiting timesglobulin (ATGAM; Upjohn Company, Kalamazoo, MI,
of one year or more. Delayed graft function was definedUSA) has been substituted for MALG. Immunosuppres-
as the requirement for dialysis in the first-week post-sive regimens were not different in older versus younger
patients. transplantation.
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Fig. 3. Graft survival with death with function censored. There was no
difference in graft survival in patients aged 18 to 59 (d) compared with
patients greater or equal to age 60 (h).
Fig. 1. Graft survival in patients aged 18 to 59 (d) was significantly
better compared with patients greater or equal to age 60 (h; P , 0.001).
Table 3. Risk factors for graft loss in patients $60 years of age
(N 5 187)
Factor Risk ratio P value
Pre-transplant malignancy 3.9 ,0.001
Pre-transplant vascular disease 2.1 0.024
Donor age .50 2.3 ,0.01
Cadaver list ,1 year 1.8 0.096
Age 65 to 70 (vs. 60 to 64) 1.7 0.062
Current tobacco usea 8.1 ,0.001
aResults for the analysis of the 155 patients for whom a smoking history was
available
in younger recipients. Ten-year graft survival was 39%
in older recipients and 53% in younger recipients. The
overall graft survival was significantly better in younger
compared with older recipients (P , 0.001). A similar
pattern was seen for patient survival, which was 92 and
Fig. 2. Patient survival in patients aged 18 to 59 (d) was significantly 95%, in the older and younger recipients, respectively,
better compared with patients greater or equal to age 60 (h; P , 0.001). at one year. Ten-year patient survival was 46% in elderly
recipients compared with 68% in younger recipients.
Overall patient survival was significantly better in
younger compared with older recipients (P , 0.001).Malignancy was categorized as either skin or nonskin
The difference in graft survival in the elderly com-malignancy. Patients with skin cancers (N 5 9) had local-
pared with younger recipients was due to more death inized disease that was excised prior to transplant. In those
the older recipients. In the elderly, 61% of graft loss waswith a history of nonskin malignancy (N 5 14), an exten-
due to death compared with 45% in younger recipients.sive evaluation was performed to rule out residual or
When graft loss due to death was censored, as shownrecurrent tumor.
in Figure 3, graft survival in patients over age 60 wasPatients using tobacco at the time of transplant were
equivalent to that of younger patients.compared with nonsmokers or former smokers who had
Predictors of poor overall graft survival, identified byquit for a minimum of two months prior to transplant.
Cox regression analysis, are shown in Table 3. A pre-
transplant history of a nonskin malignancy was associ-
RESULTS ated with an increase in graft loss. Fourteen patients
had a history of nonskin malignancy prior to transplant.Graft and patient survival rates in elderly versus
younger recipients are shown in Figures 1 and 2. One- Eleven patients had solid tumors (4 kidney, 4 bladder,
1 uterus, 1 lung, 1 prostate), and three patients had hema-year graft survival was 86% in older recipients and 88%
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Table 4. Risk factors for mortality in patients $60 years of agetologic malignancies (2 lymphoma and 1 leukemia).
None had detectable residual or recurrent disease at the Factor Risk ratio P value
time of transplant. The average time between diagnosis Pre-transplant malignancy 5.0 ,0.001
Pre-transplant vascular disease 2.2 0.02of malignancy and transplant was 7.5 years, with a range
Age . 70 (vs. 60 to 64) 2.7 0.055of 0.9 to 29.0 years. Six of these patients lost their grafts
Donor age . 50 1.9 0.056
in the first year after transplant, and overall, 10 lost their Current tobacco usea 7.9 ,0.001
grafts. The causes of graft loss were death (7), hyperacute aResults for the analysis of the 155 patients for whom a smoking history was
availablerejection (1), chronic rejection (1), and hemolytic uremic
syndrome (1). The cause of death was cardiac (3), sepsis
(1), and recurrent disease (3). There was a significant
difference between the time of the last treatment for the
all associated with worse one year graft survival (datamalignancy and the day of the transplant in patients who
not shown).died compared with those who survived with values of
Predictors of overall patient survival are shown in Ta-2.2 6 0.3 vs. 14.0 6 3.6 years (P , 0.0001), suggesting
ble 4. As was seen for graft survival, a pretransplant historythat a longer waiting period is better. Similarly, a longer
of nonskin malignancy, vascular disease, and current to-time between last treatment and the day of transplant
bacco use at the time of transplant were all associatedwas observed in the 11 patients without recurrent malig-
with worse patient survival. Cardiovascular disease wasnancy compared with the three patients with a recur-
the leading cause of death in the overall group (46%),rence: 10.9 6 3.1 years (range of 0.9 to 29 years) versus
followed by malignancy (21%) and infection (20%).2.6 6 0.4 years (range 2 to 3.4 years).
In addition, recipient age over 70 (compared with pa-Vascular disease prior to transplant was associated
tients age 60 to 64) and donor age over 50 were associatedwith a 2.1-fold increase in graft loss. A history of vascular
with worse patient survival. These same factors were alldisease was present in 47 patients and included lower
associated with worse mortality one year after transplantextremity claudication or nonhealing ulcers (14), cerebral
(data not shown). A history of diabetes prior to trans-vascular accident, carotid endarterectomy or bypass (10),
plant was also associated with worse one-year patientAAA repair (5), deep venous thrombosis (3), multiple sites
mortality, with infection being the leading cause of deathof disease (15). Graft loss occurred in 19 of the 47 (40%).
in these patients. The other factors evaluated did notThe leading cause of graft loss was patient death (74%).
predict patient survival. For the analysis of the patientsOther factors associated with poor graft survival were
for whom a smoking history was obtained, all other riskdonor age greater than 50, time on the cadaver waiting
factors remained significant. In addition, the relative risklist of less than one year, and age 65 to 70 compared
of age 65 to 70 versus 60 to 64 and delayed graft functionwith age 60 to 64. The effect of donor age on graft survival
were predictive of patient survival.was examined further by univariant analysis. Worse graft
To determine the potential impact of screening forsurvival was only seen in the cadaveric donors older than
these risk factors, patients were divided into low riskage 50 and not in the older living donors (data not shown).
and high risk groups based on the presence or absenceThe other factors evaluated, including donor source, de-
of the major risk factors: pretransplant vascular disease,layed graft function, a history of coronary artery disease,
pretransplant nonskin malignancy, and tobacco use atand diabetes, did not predict overall graft survival.
the time of transplant. Graft survival was evaluated inTobacco use at the time of transplant was associated
patients with none of these risk factors (low risk, N 5with worse graft survival compared with those who never
142) and in patients with one or more of these risk factorssmoked or who previously smoked but quit at least two
(high risk, N 5 64). Graft survival in both groups wasmonths prior to transplant. Eleven patients continued
then compared with graft survival in younger recipientsto use tobacco at the time of transplant. Seven (64%) of
(Fig. 4). Graft survival in low-risk elderly recipients wasthese patients lost their grafts, all because of death. Death
equivalent to that of younger recipients with a 10-yearwas due to cardiovascular events in three (43%), infec-
graft survival of 50% in older low-risk recipients com-tion in two (29%), and malignancy in two (29%). In this
pared with 53% in younger recipients. Graft survival inanalysis of the patients in whom a smoking history was
the high-risk older recipients was significantly worse thanavailable, significant predictors of graft survival were simi-
that of both the low-risk older recipient (P , 0.0001)lar to that of the larger group, except for vascular disease
and the younger recipients (P , 0.0001) with a one andand time on the cadaver waiting list of less than one year.
ten year survival of 74 and 15%, respectively. A similarSeveral of these factors were predictors of graft loss
analysis was done for patient survival and demonstratedin the first year after transplant (data not shown). In-
improved survival in patients without pretransplant vas-creasing recipient age, a pretransplant history of nonskin
cular disease, pretransplant nonskin malignancy, and to-malignancy prior to transplant, time on the cadaver wait-
ing list of less than year, and current tobacco use were bacco use compared with patients with one or more of
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Fig. 4. Graft survival in patients aged 18 to 59 (d) compared with Fig. 5. Patient survival in patients aged 18 to 59 (d) compared with
patients greater or equal to age 60 with (j; P , 0.0001) or without (h, patients greater or equal to age 60 with (j; P , 0.0001) or without (h;
P 5 NS) the risk factors of pretransplant vascular disease, nonskin P 5 NS) the risk factors of pretransplant vascular disease, nonskin
malignancy, or current tobacco use. malignancy, or current tobacco use.
ease-free interval prior to transplant. The poor survivalthese risk factors (P , 0.0001; Fig. 5). In the presence
of the remaining patients suggests that a history of malig-of one of these risk factors, ten year mortality decreased
nancy may predispose to death in other ways. such asfrom 51 to 31%.
an increased susceptibility to infection related to prior
chemotherapy or radiation treatment.
DISCUSSION A history of cerebral, aortic, or lower extremity arte-
The rapid growth of the elderly ESRD population has rial disease or of deep venous thrombosis was associated
raised important issues regarding the choice of renal with poor outcome. In contrast, coronary artery disease
replacement therapy in these patients. Comparisons be- was not associated with poor outcome. This may be due
tween dialysis and transplantation outcomes are con- to the aggressive screening and treatment of coronary
founded by selection bias, with the generally healthier artery disease in our patients prior to transplantation.
patients being referred for transplantation. Despite this Since 47% of these patients with peripheral vascular
limitation, transplantation appears to improve both pa- disease died from a cardiac cause, the finding of periph-
tient survival and quality of life [16]. As we have shown eral vascular disease should be an impetus to aggressively
in our patient population, and consistent with findings manage all vascular disease in these patients.
in the literature, short-term graft survival is excellent in Tobacco use at the time of transplant was associated
the majority of older renal failure patients [6–13]. This with a dramatically increased risk of poor outcome, while
excellent graft survival occurred despite a higher per- survival in patients who smoked previously but quit at
centage of cadaveric donors in older patients. Longer- least two months prior to transplant was equivalent to
term graft survival is decreased in the older transplant that of nonsmokers. Smoking has been previously identi-
recipients with patient death with a functioning kidney fied as a risk factor for the development and/or progres-
being the major cause of graft loss. With the increasing sion of renal disease in the nontransplant setting [17, 18].
pressures of an aging ESRD population and the shortage Possible explanations for the adverse effect of smoking
of donor kidneys, we felt it was important to define include increased susceptibility to respiratory infection
factors identifying patients at risk for death or graft loss. or vascular disease. In addition, both cigarette smoking
Identification of such risk factors would facilitate selec- and immunosuppressive agents such as cyclosporine are
tion of older transplant candidates and perhaps suggest known to induce vascular endothelial dysfunction and
specific interventions prior to transplant to reduce risk. injury [17]. A synergistic effect may exist between to-
In this study, we have identified risk factors predicting bacco use and cyclosporine, resulting in an increase in
poor outcome. A history of nonskin malignancy was vascular events. This synergism may explain the absence
associated with very poor graft and patient survival. of an effect on patient or graft survival in patients who
Three of these patients died of metastatic disease despite quit smoking even two months prior to the transplant.
extensive screening to rule out residual or recurrent tu- Consistent with the findings of others, graft and patient
mor prior to transplant, and an average disease-free in- survival were worse in recipients of cadaver kidneys from
terval of 2.6 years for these patients compared with 10.9 donors older than age 50 [19]. Older recipients may be
years in patients without recurrent malignancy, sug- disadvantaged to a greater extent than younger recipi-
ents as they have an increased risk of death [19]. Thegesting that elderly patients may require a longer dis-
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effect of donor age was not observed in recipients of plants in the elderly have become better accepted, the
kidneys from older living donors, a finding that was ob- criteria for patient selection have undoubtedly been re-
served in the UNOS Scientific Registry [20]. The time laxed. Clinical management has also improved, particu-
on the cadaver waiting list of less than one year was a larly in the treatment of infectious complications such
risk factor for poor graft survival. One possible explana- as cytomegalovirus. Despite these changes in patient se-
tion for this is that in cadaver recipients, time on the lection and treatment, graft and patient survival have
waiting list serves to select healthier candidates, while remained relatively stable to improved (data not shown).
the sicker candidates either die or develop problems that Predicting clinical outcome based on the risk factors
cause them to be removed from the list. Patient survival identified in this study may not universally apply to the
was not affected by time on the cadaver waiting list entire 17-year period of follow-up.
of less than one year. The reason for this discrepancy The current study was limited to evaluation of graft
between graft and patient survival is unclear. In the case and patient survival in elderly renal transplant recipients;
of the recipients with living donors, the time of transplant however, anecdotal experience suggests that morbidity
is optional and can thus be optimized according to each after renal transplantation in elderly recipients may dif-
patient’s particular situation. Survival in the patients fer from that of younger patients [2, 4]. Differences in the
aged 70 or greater was worse than for patients age 60 incidence of steroid myopathy, osteoporosis, and post-
to 64. However, graft survival was not adversely affected transplant diabetes, as well as risk factors for these com-
in these older patients. plications, need to be determined in this population and
Most importantly, graft and patient survival was sig- compared with that in younger patients.
nificantly better in patients aged 60 or greater without In conclusion, graft survival in patients aged 60 or
one of the major risk factors of a history of pretransplant older is excellent, with most graft loss occurring second-
malignancy, vascular disease, or current smoking history ary to patient death. A pretransplant history of malig-
compared with older patients with one or more of these nancy or vascular disease and a history of smoking at
risk factors. In fact, graft survival in these low-risk pa- the time of transplant were all associated with an in-
tients was equivalent to that of younger patients aged creased risk of graft loss and patient death. Screening
18 to 59. The potential effect of screening for these risk for these risk factors enabled selection of low-risk elderly
factors and either modifying risks prior to transplant patients who had graft and survival outcomes similar to
(mandating smoking cessation prior to transplant) or younger patients.
reconsidering timing or advisability of transplant (recent
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